MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
lisocabtagene maraleucel Sensitive: A2 - Guideline
|
MYC rearrangement + BCL6 rearrangement
|
NHL
|
MYC rearrangement + BCL6 rearrangement
|
NHL
|
ibrutinib Sensitive: C3 – Early Trials
|
ibrutinib Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
EPOCH-R Sensitive: C3 – Early Trials
|
EPOCH-R Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL6 rearrangement
|
Follicular Lymphoma
|
MYC rearrangement + BCL6 rearrangement
|
Follicular Lymphoma
|
EPOCH-R Resistant: C3 – Early Trials
|
EPOCH-R Resistant: C3 – Early Trials
|
MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
MYC rearrangement + BCL6 rearrangement
|
Diffuse Large B Cell Lymphoma
|
C-RICE Sensitive: C3 – Early Trials
|
C-RICE Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL6 rearrangement
|
Lymphoma
|
MYC rearrangement + BCL6 rearrangement
|
Lymphoma
|
HZX-02-059 Sensitive: D – Preclinical
|
HZX-02-059 Sensitive: D – Preclinical
|